In every effort to make research information to a greater degree accessible to the community, Mayo Clinic’s three transformational centers — the Center during the term of Individualized Medicine, the Center for Regenerative Medicine, and the Mayo Clinic Robert D. and Patricia E. Kern Center because the Science of Health Care Delivery — be seized of joined forces with Madonna Living Community to venture a speaker series for members of the place of abode as well as the local common at large.
Meeting bi-monthly, Mayo Clinic speakers apportion their research on topics relevant to this congregation.
On Tuesday, October 20, Dr. Richard Weinshilboum spoke end for end Pharmacogenomics: Genomics and Drug Response to residents and guests at Madonna’s Sister Generose Auditorium.
Dr. Weinshilboum is the Principal Investigator of the Mayo Clinic Pharmacogenomics Research Network (PGRN), funded ~ means of the National Institutes of Health. This study is every integrated, multidisciplinary, pharmacogenomics research effort, what one. applies a “genotype-to-phenotype” exploration strategy.
He explained pharmacogenomics to the impute audience as “the study of the role of heritage in individual variation in drug replication phenotypes.” Clinically, the goals of pharmacogenomics take in avoiding adverse drug reactions, maximizing effectiveness of prescribed drugs, and reason which drugs will work best for a particular patient.
With drug therapies today life designed for an average patient, Dr. Weinshilboum reminded attendees, “we are Minnesotans, and like Garrison Keillor in the same state often points out – here in the put on shore of Lake Wobegon, we are altogether above average.”
With this in common-sense, research is being done to watch at variations in genes and in what state these affect our response to therapeutic drugs. Using examples of childhood leukemia, affections cancer, and depression, he demonstrated by what means genetically sequencing a patient’s DNA be able to help determine how they will individually cor~ to a drug treatment, and in what way having this information can help the prescribing doctor determine the right drug at the ~ful dose for their patients.
The nearest presentation in the Madonna Living Community’s presiding officer series will feature Dr. Ramona DeJesus from Primary Care Internal Medicine and the Center on the side of the Science of Health Care Delivery declamation on the topic of complex care.
The common is welcome to attend this fact, which will take place December 17, 1 p.m., Madonna Towers, 4001 19th Avenue NW, Rochester, MN 55901. Free parking is available in the Pax Christi parking portion along 41st Street NW.
Dr. Richard Weinshilboum is a Professor of Pharmacology and Medicine and Mary Lou and John H. Dasburg Professor of Cancer Genomics Research and he directs the Pharmacogenomics Program in the Center in spite of Individualized Medicine.
Although the effect was moderate, the researchers report that it could own a significant impact at a populousness level, since the differences found in the study would exist associated with a 10 percent least bit in rates of high blood pressure and a 7 to 10 percent dwindle in cardiovascular disease.